Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis and Metrics

Regeneron Pharmaceuticals

NASDAQ: REGN

$655.96 ▲ +4.05 (+0.62%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap68.28 Bn

P/E15.44

P/S4.58

Div. Yield0.01

ROIC (Qtr)0.04

Total Debt (Qtr)1.99 Bn

Revenue Growth (1y) (Qtr)19.04

Add ratio to table…

About

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents develops manufactures and commercializes medicines for patients with serious diseases. The company focuses on eye diseases allergic and inflammatory conditions cancer cardiovascular and metabolic disorders neurological diseases hematologic conditions infectious diseases and rare disorders. Its strategy rests on a strong foundation in scientific research and drug development using proprietary technologies and builds on that foundation with clinical development manufacturing and commercial capabilities. The goal is to continue advancing as an integrated multi product biotechnology company providing important medicines for preventing and treating human diseases.

Regeneron generates revenue primarily from the sale of its approved products and from collaboration agreements with partners. Product sales include ophthalmology therapies such as EYLEA and EYLEA HD immunology agents like Dupixent and Kevzara oncology treatments such as Libtayo cardiovascular drugs like Praluent and Evkeeza and other marketed items. The company also earns collaboration revenue from profit sharing and royalty arrangements with Sanofi Bayer and other partners. In addition it receives revenue from the sale of bulk drug material to collaborators and from milestone payments tied to development programs.

The company operates through the following segments.

• This segment encompasses the discovery of new drug targets the development of biologic therapies the manufacturing of clinical and commercial supplies and the commercialization of approved medicines worldwide.

Regeneron holds a strong position in several therapeutic areas where its products compete with established biopharmaceutical firms. In ophthalmology its EYLEA franchise faces competition from products such as Vabysmo Lucentis Avastin and various biosimilars. In immunology Dupixent competes with drugs like Dupixent's rivals including Adbry Cibinqo Rinvoq and others. In oncology Libtayo competes with checkpoint inhibitors such as Keytruda Opdivo Tecentriq and others. The company's competitive advantages stem from its proprietary technology platforms including the Trap technology and the VelociSuite suite which enable rapid discovery and production of fully human antibodies and bispecific molecules. These capabilities support a deep pipeline and allow for differentiated mechanisms of action.

Regeneron sells its products to wholesalers specialty distributors pharmacies hospitals government agencies physicians and other healthcare providers. The company's revenue is concentrated with two major customers each accounting for more than ten percent of total gross product revenue and together representing about seventy seven percent of sales. While the specific names of these customers are not disclosed they are understood to be large distributors that serve the broader healthcare market.

Investment Thesis

▲ Bull case

Regeneron is positioned for sustained long-term growth driven by the expanding indications and global penetration of DUPIXENT, which has demonstrated resilient performance with 31% year-over-year global net sales growth in Q1 FY26 to $4.9 billion and continues to benefit from new approvals in allergic fungal rhinosinusitis and chronic spontaneous urticaria in children aged 2-11, significantly broadening its addressable market across age groups and disease areas, with annualized global net sales nearing $20 billion and substantial room for further market penetration, particularly as the company advances next-generation therapeutics like long-acting IL-13 and IL-4 antibodies that could extend dosing intervals and enhance durability of response, thereby reinforcing DUPIXENT’s role as a cornerstone of its immunology franchise while mitigating concerns about patent expiration through lifecycle innovation rather than simple replication.
The company’s strategic investments in high-potential pipeline assets are beginning to derisk, with garetosmab for fibrodysplasia ossificans progressiva (FOP) having received FDA priority review and a PDUFA date in August 2026, supported by data showing prevention of 99% of abnormal bone formation, which, if approved, would establish Regeneron as the first and only provider of a disease-modifying treatment in a devastating ultra-rare condition with significant unmet need and pricing power, while the recent FDA approval of Otarmeni for genetic hearing loss—offered free in the U.S.—underscores the company’s commitment to transformative science and enhances its reputation for delivering breakthrough therapies in areas neglected by larger peers, creating goodwill and long-term strategic optionality.
Regeneron is building a differentiated position in the obesity and cardiovascular risk reduction market through its collaboration on olatorepatide, a dual GLP/GIP receptor agonist, which demonstrated up to 19% mean body weight loss at week 48 in Phase II trials in China with favorable gastrointestinal tolerability, and when combined with Praluent (alirocumab), has the potential to deliver superior lipid-lowering effects beyond current GLP-1 agonists, addressing a critical gap in cardiovascular risk management for obese and diabetic patients, a market where existing therapies often leave residual dyslipidemia, and Regeneron’s ability to price competitively while offering added cardiometabolic benefits could capture meaningful share in a rapidly growing segment projected to exceed $100 billion in annual sales by 2030.
The company is advancing a novel and underappreciated opportunity in intracellular targeting through its collaboration with Parabilis Medicines on Antibody-Helicon™ Conjugates (AHCs), which leverages stabilized cell-penetrant alpha-helical peptides to modulate historically undruggable intracellular targets such as transcription factors and signaling proteins, with an upfront $50 million payment and potential for up to $2.2 billion in milestones, representing a low-cost, high-optionality bet on a platform that could unlock entirely new drug classes in oncology and beyond, particularly as traditional modalities fail against flat protein-protein interfaces, and Regeneron’s expertise in antibody discovery and manufacturing positions it to lead development and commercialization should early proof-of-concept succeed.
Capital allocation remains a significant underappreciated strength, with the Board’s authorization of a new $3 billion share repurchase program bringing total availability to approximately $3.4 billion as of Q1 FY26, reflecting strong confidence in intrinsic value and financial flexibility, especially given the company’s $15.8 billion net cash position and $848 million of free cash flow generated in the quarter, enabling Regeneron to return capital aggressively while continuing to fund R&D at $1.4 billion per quarter, a balance that supports both innovation and shareholder enrichment without reliance on debt or dilution.

Regeneron is positioned for sustained long-term growth driven by the expanding indications and global penetration of DUPIXENT, which has demonstrated resilient performance with 31% year-over-year global net sales growth in Q1 FY26 to $4.9 billion and continues to benefit from new approvals in allergic fungal rhinosinusitis and chronic spontaneous urticaria in children aged 2-11, significantly broadening its addressable market across age groups and disease areas, with annualized global net sales nearing $20 billion and substantial room for further market penetration, particularly as the company advances next-generation therapeutics like long-acting IL-13 and IL-4 antibodies that could extend dosing intervals and enhance durability of response, thereby reinforcing DUPIXENT’s role as a cornerstone of its immunology franchise while mitigating concerns about patent expiration through lifecycle innovation rather than simple replication.
The company’s strategic investments in high-potential pipeline assets are beginning to derisk, with garetosmab for fibrodysplasia ossificans progressiva (FOP) having received FDA priority review and a PDUFA date in August 2026, supported by data showing prevention of 99% of abnormal bone formation, which, if approved, would establish Regeneron as the first and only provider of a disease-modifying treatment in a devastating ultra-rare condition with significant unmet need and pricing power, while the recent FDA approval of Otarmeni for genetic hearing loss—offered free in the U.S.—underscores the company’s commitment to transformative science and enhances its reputation for delivering breakthrough therapies in areas neglected by larger peers, creating goodwill and long-term strategic optionality.
Regeneron is building a differentiated position in the obesity and cardiovascular risk reduction market through its collaboration on olatorepatide, a dual GLP/GIP receptor agonist, which demonstrated up to 19% mean body weight loss at week 48 in Phase II trials in China with favorable gastrointestinal tolerability, and when combined with Praluent (alirocumab), has the potential to deliver superior lipid-lowering effects beyond current GLP-1 agonists, addressing a critical gap in cardiovascular risk management for obese and diabetic patients, a market where existing therapies often leave residual dyslipidemia, and Regeneron’s ability to price competitively while offering added cardiometabolic benefits could capture meaningful share in a rapidly growing segment projected to exceed $100 billion in annual sales by 2030.
The company is advancing a novel and underappreciated opportunity in intracellular targeting through its collaboration with Parabilis Medicines on Antibody-Helicon™ Conjugates (AHCs), which leverages stabilized cell-penetrant alpha-helical peptides to modulate historically undruggable intracellular targets such as transcription factors and signaling proteins, with an upfront $50 million payment and potential for up to $2.2 billion in milestones, representing a low-cost, high-optionality bet on a platform that could unlock entirely new drug classes in oncology and beyond, particularly as traditional modalities fail against flat protein-protein interfaces, and Regeneron’s expertise in antibody discovery and manufacturing positions it to lead development and commercialization should early proof-of-concept succeed.
Capital allocation remains a significant underappreciated strength, with the Board’s authorization of a new $3 billion share repurchase program bringing total availability to approximately $3.4 billion as of Q1 FY26, reflecting strong confidence in intrinsic value and financial flexibility, especially given the company’s $15.8 billion net cash position and $848 million of free cash flow generated in the quarter, enabling Regeneron to return capital aggressively while continuing to fund R&D at $1.4 billion per quarter, a balance that supports both innovation and shareholder enrichment without reliance on debt or dilution.

▼ Bear case

Regeneron faces growing near-term headwinds in its ophthalmology franchise, particularly with EYLEA, as U.S. net sales declined 36% year-over-year to $473 million in Q1 FY26, driven by ongoing conversion to EYLEA HD, competitive pressures from biosimilars and rival treatments like Roche’s Vabysmo, and patient affordability issues, with the modest reduction in EYLEA inventory expected to negatively impact second-quarter sales by approximately $20 million, and while EYLEA HD grew 52% year-over-year to $468 million, its sequential decline due to wholesaler inventory adjustments suggests demand may not be as robust as implied by year-over-year comparisons, raising concerns about the sustainability of the franchise transition and the company’s ability to offset legacy product erosion with the higher-dose version alone.
The company’s oncology pipeline is encountering significant validation risks, highlighted by the failure of fianlimab plus Libtayo to meet the primary endpoint in a late-stage trial for advanced melanoma, where median progression-free survival was approximately five months better than Keytruda but not statistically significant, undermining confidence in the LAG-3/PD-1 bispecific approach and increasing pressure on upcoming readouts from the head-to-head trial against Opdualag, especially as analysts express low confidence in a positive outcome, and with Itepekimab’s prior failure in COPD and limited progress in chronic rhinosinusitis with nasal polyps (results expected 2027), Regeneron’s immunotherapy franchise beyond Libtayo in adjuvant cutaneous squamous cell carcinoma lacks near-term catalysts, leaving the oncology segment vulnerable to overreliance on a single asset in a crowded and rapidly evolving market.
Despite optimistic commentary, Regeneron’s metabolic pipeline efforts through olatorepatide remain early-stage and geographically limited, with Phase II data derived solely from Chinese patients, raising questions about generalizability to global populations, and while the company plans to initiate two global Phase III programs later in 2026, the timeline for meaningful data readouts extends into 2027 or beyond, leaving near-term growth dependent on DUPIXENT and EYLEA HD, and the potential cardiovascular benefit from combining olatorepatide with Praluent, while theoretically compelling, lacks clinical validation in diverse cohorts, creating a risk that the program fails to differentiate sufficiently in a market increasingly dominated by tirzepatide and emerging oral agents with superior convenience and efficacy profiles.
The company’s reliance on the Sanofi collaboration for DUPIXENT profits introduces structural vulnerability, as while collaboration revenue grew 42% year-over-year to $1.5 billion in Q1 FY26, the development balance is expected to be fully repaid by end of Q2 FY26, after which Sanofi collaboration revenue will step up to reflect Regeneron’s full share of profits, potentially increasing earnings volatility if DUPIXENT growth decelerates, and although management expressed openness to lifecycle expansion discussions with Sanofi’s new CEO, there is no guaranteed path to co-develop or co-commercialize next-generation IL-4/IL-13 assets within the collaboration, leaving Regeneron to potentially bear full commercial and development costs for its pipeline extensions, which could strain R&D efficiency if Sanofi does not extend partnership beyond the current DUPIXENT molecule.
Regeneron’s ambitious forays into novel modalities such as siRNA-based therapies (e.g., cemdisiran for PNH and GMG) and intracellular targeting via the Parabilis collaboration carry significant scientific and execution risk, as cemdisiran, while showing promising Phase III data in generalized myasthenia gravis with a 2.3 point placebo-adjusted improvement in MG-ADL, remains dependent on FDA approval in Q4 FY26, and any delay or complete response letter could undermine confidence in the company’s ability to translate innovative mechanisms into approved therapies, while the Parabilis deal, though low in upfront cost, depends on early-stage target validation and complex protein-protein interaction modulation, a historically challenging area with high failure rates, meaning the $2.2 billion milestone potential is highly speculative and may never materialize if preclinical proof-of-concept fails to translate to in vivo efficacy, representing a material opportunity cost given the company’s $1.4 billion quarterly R&D spend.

Regeneron faces growing near-term headwinds in its ophthalmology franchise, particularly with EYLEA, as U.S. net sales declined 36% year-over-year to $473 million in Q1 FY26, driven by ongoing conversion to EYLEA HD, competitive pressures from biosimilars and rival treatments like Roche’s Vabysmo, and patient affordability issues, with the modest reduction in EYLEA inventory expected to negatively impact second-quarter sales by approximately $20 million, and while EYLEA HD grew 52% year-over-year to $468 million, its sequential decline due to wholesaler inventory adjustments suggests demand may not be as robust as implied by year-over-year comparisons, raising concerns about the sustainability of the franchise transition and the company’s ability to offset legacy product erosion with the higher-dose version alone.
The company’s oncology pipeline is encountering significant validation risks, highlighted by the failure of fianlimab plus Libtayo to meet the primary endpoint in a late-stage trial for advanced melanoma, where median progression-free survival was approximately five months better than Keytruda but not statistically significant, undermining confidence in the LAG-3/PD-1 bispecific approach and increasing pressure on upcoming readouts from the head-to-head trial against Opdualag, especially as analysts express low confidence in a positive outcome, and with Itepekimab’s prior failure in COPD and limited progress in chronic rhinosinusitis with nasal polyps (results expected 2027), Regeneron’s immunotherapy franchise beyond Libtayo in adjuvant cutaneous squamous cell carcinoma lacks near-term catalysts, leaving the oncology segment vulnerable to overreliance on a single asset in a crowded and rapidly evolving market.
Despite optimistic commentary, Regeneron’s metabolic pipeline efforts through olatorepatide remain early-stage and geographically limited, with Phase II data derived solely from Chinese patients, raising questions about generalizability to global populations, and while the company plans to initiate two global Phase III programs later in 2026, the timeline for meaningful data readouts extends into 2027 or beyond, leaving near-term growth dependent on DUPIXENT and EYLEA HD, and the potential cardiovascular benefit from combining olatorepatide with Praluent, while theoretically compelling, lacks clinical validation in diverse cohorts, creating a risk that the program fails to differentiate sufficiently in a market increasingly dominated by tirzepatide and emerging oral agents with superior convenience and efficacy profiles.
The company’s reliance on the Sanofi collaboration for DUPIXENT profits introduces structural vulnerability, as while collaboration revenue grew 42% year-over-year to $1.5 billion in Q1 FY26, the development balance is expected to be fully repaid by end of Q2 FY26, after which Sanofi collaboration revenue will step up to reflect Regeneron’s full share of profits, potentially increasing earnings volatility if DUPIXENT growth decelerates, and although management expressed openness to lifecycle expansion discussions with Sanofi’s new CEO, there is no guaranteed path to co-develop or co-commercialize next-generation IL-4/IL-13 assets within the collaboration, leaving Regeneron to potentially bear full commercial and development costs for its pipeline extensions, which could strain R&D efficiency if Sanofi does not extend partnership beyond the current DUPIXENT molecule.
Regeneron’s ambitious forays into novel modalities such as siRNA-based therapies (e.g., cemdisiran for PNH and GMG) and intracellular targeting via the Parabilis collaboration carry significant scientific and execution risk, as cemdisiran, while showing promising Phase III data in generalized myasthenia gravis with a 2.3 point placebo-adjusted improvement in MG-ADL, remains dependent on FDA approval in Q4 FY26, and any delay or complete response letter could undermine confidence in the company’s ability to translate innovative mechanisms into approved therapies, while the Parabilis deal, though low in upfront cost, depends on early-stage target validation and complex protein-protein interaction modulation, a historically challenging area with high failure rates, meaning the $2.2 billion milestone potential is highly speculative and may never materialize if preclinical proof-of-concept fails to translate to in vivo efficacy, representing a material opportunity cost given the company’s $1.4 billion quarterly R&D spend.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2024)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2024)

Peer Comparison

Create an account

Sign In

Reset Password